Inhibition of T cell activation and autoimmune diabetes using a B cell surface–linked CTLA-4 agonist
J. Clin. Invest. Brian T. Fife, et al. 116:2252 doi:10.1172/JCI27856 [Go to this article.]

Figure 4
scαCTLA-4 Tg⁺ B cells inhibit allogeneic T cell proliferation and cytokine production during a MLR T cell response. LPS-preactivated B cells from FVB WT control or FVB.scαCTLA-4 Tg⁺ mice were incubated with purified (A) C57BL/6 or (B) C57BL/6.CTLA-4 KO responder T cells in a MLR. Proliferation was assessed by tritiated thymidine incorporation. (C and D) Culture supernatant from WT C57BL/6 responder T cells demonstrates that scαCTLA-4 Tg⁺ B cells significantly reduced (C) IFN-γ and (D) IL-2 cytokine production after 48 hours of coculture. Responder T cells were cultured at 2 × 10⁴ per well, and stimulator B cells were cultured at either 0, 1, or 2 × 10⁵ per well as indicated. Results illustrated are representative of at least 2 independent experiments.